REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo...
Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assets Menlo’s serlopitant for pruritus associated with prurigo nodularis (“PN”) complements Foamix’s existing portfolio and addresses a significant unmet medical need...
– Pivotal Data from two Phase 3 Trials in Prurigo Nodularis Expected March/April 2020 and Phase 2 Trial Results in Chronic Pruritus of Unknown Origin Expected January/February 2020 – REDWOOD CITY, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO),...
– Pivotal results expected in March/April 2020 – – Details of the program to be reviewed at company’s Investor Day today in NY – REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical...
-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant- -Discussion to Feature two Prominent Key Opinion Leaders Well Versed in the Unmet Needs of the Prurigo Nodularis and Chronic Pruritus of Unknown Origin Patient Populations- REDWOOD...
REDWOOD CITY, Calif., [October 11, 2019] — Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritus in patients with psoriasis in an oral presentation at the...
REDWOOD CITY, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta, chief executive officer of Menlo...
Results expected in Q1 2020 REDWOOD CITY, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced that it has completed patient enrollment in its Phase 2 clinical trial evaluating the safety and efficacy of...
REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball, chief financial officer of Menlo...
August 1, 2019 at 4:05 PM EDT Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020 Results from Serlopitant Phase 3 Clinical Trials for the Treatment of Pruritus with Prurigo Nodularis Anticipated in H1 2020 REDWOOD CITY,...
